Report overview
This report aims to provide a comprehensive presentation of the global market for Cancer Antibody Drug Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Antibody Drug Conjugates. This report contains market size and forecasts of Cancer Antibody Drug Conjugates in global, including the following market information:
Global Cancer Antibody Drug Conjugates Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Cancer Antibody Drug Conjugates Market Sales, 2018-2023, 2024-2029, (K Dose)
Global top five Cancer Antibody Drug Conjugates companies in 2022 (%)
The global Cancer Antibody Drug Conjugates market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
First & Second Generation ADCs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec and Nordic Nanovector, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Antibody Drug Conjugates manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Antibody Drug Conjugates Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, by Type, 2022 (%)
First & Second Generation ADCs
Third Generation ADCs
Global Cancer Antibody Drug Conjugates Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Cancer Antibody Drug Conjugates Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Dose)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Antibody Drug Conjugates revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Cancer Antibody Drug Conjugates revenues share in global market, 2022 (%)
Key companies Cancer Antibody Drug Conjugates sales in global market, 2018-2023 (Estimated), (K Dose)
Key companies Cancer Antibody Drug Conjugates sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cancer Antibody Drug Conjugates, market overview.
Chapter 2: Global Cancer Antibody Drug Conjugates market size in revenue and volume.
Chapter 3: Detailed analysis of Cancer Antibody Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cancer Antibody Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cancer Antibody Drug Conjugates capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
